Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study.

摘要: Abstract Introduction Extracorporeal shock wave therapy (ESWT) for treatment of Peyronie's disease (PD) is controversial. Aim To study the efficacy ESWT by a placebo-controlled, randomized trial. Methods Patients with PD (n = 102) were randomly assigned 51) to each group (ESWT or placebo). All patients given 6 weekly treatments. in ESWT-group received 2,000 waves per session, using Piezoson 100 lithotripter (Richard Wolf, Knittlingen, Germany). placebo-group treated interposition plastic membrane, which prevented any transmission waves. Main Outcome Measures Primary end point was decrease pain between baseline and after 4 weeks follow-up. Secondary points changes deviation, plaque size, sexual function. Pain assessed visual analog scale. Deviation measured goniometer artificial erection Alprostadil (Viridal ® , Schwarz Pharma, Monheim, Plaque size ruler function scale regarding ability perform intercourse. Results Overall, only 45 experienced at baseline. In subgroup analysis these patients, decreased 17/20 (85.0%) 12/25 (48.0%) placebo ( P 0.013, relative risk [RR] 0.29, 95% confidence interval: 0.09–0.87). Penile deviation not reduced 0.66) but worsened 20/50 (40%) 12/49 (24.5%) placebo-group, respectively 0.133). reduction different two groups 0.33). Additional, increased five (10.9%) only. An improvement could be verified 0.126, RR 0.46). Conclusions Despite some potential benefit regard reduction, it should emphasized that usually resolves spontaneously time. Given this fact may worsen ESWT, cannot recommended. Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. disease: prospective, randomized, single-blind study. J Sex Med 2013;10:2815–2821.